Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.

Core Viewpoint - Denmark's Novo is making an offer of $56.50 per share in cash for Metsera, with the potential for an additional $21.25 per share contingent on achieving clinical and regulatory milestones [1] Group 1 - Novo's initial cash offer for Metsera is set at $56.50 per share [1] - The total potential value of the offer could reach $77.75 per share if certain milestones are met [1] - The additional $21.25 per share is based on specific clinical and regulatory achievements [1]